{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:18:29Z","timestamp":1788185909854,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["grant H24-Clinical Study General-014"],"award-info":[{"award-number":["grant H24-Clinical Study General-014"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12185-026-04213-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:35:39Z","timestamp":1778297739000},"page":"390-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treosulfan-based conditioning for hematopoietic stem cell transplantation in mucopolysaccharidosis: a pilot study"],"prefix":"10.1007","volume":"124","author":[{"given":"Takashi","family":"Koike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6508-5496","authenticated-orcid":false,"given":"Hiromasa","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"3","key":"4213_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12185-024-03810-3","volume":"120","author":"H Yabe","year":"2024","unstructured":"Yabe H, Koike T, Yamamoto S, Otsuka K, Nakajima J, Shibata M, et al. Allogeneic stem cell transplantation for inherited metabolic disorders: 35\u00a0years\u2019 experience at a single institution. Int J Hematol. 2024;120(3):365\u201374.","journal-title":"Int J Hematol"},{"key":"4213_CR2","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O\u2019Meara A, Veys P, Alain Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164\u201372.","journal-title":"Blood"},{"issue":"3","key":"4213_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","volume":"107","author":"A Tanaka","year":"2012","unstructured":"Tanaka A, Okuyama T, Suzuki Y, Sakai N, Takakura H, Sawada T, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab. 2012;107(3):513\u201320.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4213_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","volume":"117","author":"H Yabe","year":"2016","unstructured":"Yabe H, Tanaka A, Chinen Y, Kato S, Sawamoto K, Yasuda E, et al. Hematopoietic stem cell transplantation for Morquio A syndrome. Mol Genet Metab. 2016;117(2):84\u201394.","journal-title":"Mol Genet Metab"},{"issue":"16","key":"4213_CR5","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1182\/blood-2010-10-312082","volume":"117","author":"MA Slatter","year":"2011","unstructured":"Slatter MA, Rao K, Amrolia P, Flood T, Abinun M, Hambleton S, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117(16):4367\u201375.","journal-title":"Blood"},{"issue":"12","key":"4213_CR6","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/bmt.2015.171","volume":"50","author":"MA Slatter","year":"2015","unstructured":"Slatter MA, Boztug H, P\u00f6tschger U, Sykora KW, Lankester A, Yaniv I, et al. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50(12):1536\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"4213_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2017.11.009","volume":"24","author":"MA Slatter","year":"2018","unstructured":"Slatter MA, Rao K, Hamid IJA, Nademi Z, Chiesa R, Elfeky R, et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol Blood Marrow Transplant. 2018;24:529\u201336.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"4213_CR8","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/s41409-020-0866-9","volume":"55","author":"A Leiper","year":"2020","unstructured":"Leiper A, Houwing M, Davies EG, Rao K, Burns S, Morris E, et al. Anti-M\u00fcllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens. Bone Marrow Transplant. 2020;55(10):1985\u201395.","journal-title":"Bone Marrow Transplant"},{"key":"4213_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/bmt.2009.4","volume":"44","author":"A Gratwohl","year":"2009","unstructured":"Gratwohl A. Folinic acid administration following MTX as prophylaxis for GVHD. Bone Marrow Transplant. 2009;44:257.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4213_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","volume":"17","author":"ER Nemecek","year":"2011","unstructured":"Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2011;17(3):341\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4213_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.bmt.1705718","volume":"40","author":"JJ Boelens","year":"2007","unstructured":"Boelens JJ, Wynn RF, O\u2019Meara A, Veys P, Bertrand Y, Souillet G, et al. Outcomes of hematopoietic stem cell transplantation for Hurler\u2019s syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007;40:225\u201333.","journal-title":"Bone Marrow Transplant"},{"key":"4213_CR12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","volume":"21","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Jones SA, Bonney D, Borrill RE, Coussons M, Mercer J, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21:1106\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4213_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10545-016-0006-2","volume":"40","author":"NJ Rodgers","year":"2017","unstructured":"Rodgers NJ, Kaizer AM, Miller WP, Rudser KD, Orchard PJ, Braunlin EA. Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience. J Inherit Metab Dis. 2017;40:271\u201380.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"4213_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53(2):138\u201345.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"4213_CR15","first-page":"4209","volume":"6","author":"ME Scheulen","year":"2000","unstructured":"Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM, et al. Clinical phase 1 dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 2000;6(11):4209\u201316.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4213_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14960","volume":"179","author":"MYEC Stoep","year":"2017","unstructured":"Stoep MYEC, Bertaina A, Brink MHT, Bredius RG, Smiers FJ, Wanders DCM, et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br J Haematol. 2017;179(5):772\u201380.","journal-title":"Br J Haematol"},{"issue":"12","key":"4213_CR17","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.bbmt.2014.08.020","volume":"20","author":"LM Burroughs","year":"2014","unstructured":"Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J, et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow Transplant. 2014;20(12):1996\u20132003.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"4213_CR18","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/s41409-020-0869-6","volume":"55","author":"K Kalwak","year":"2020","unstructured":"Kalwak K, Mielcarek M, Patrick K, Styczynski J, Bader P, Corbacioglu S, et al. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Trasnplant. 2020;55(10):1996\u20132007.","journal-title":"Bone Marrow Trasnplant"},{"issue":"1","key":"4213_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","volume":"59","author":"KW Sykora","year":"2024","unstructured":"Sykora KW, Beier R, Schulz A, Cesaro S, Greil J, Gozdzik J, et al. Treosulfan vs busulfan conditioning for allogeneic BMT in children with nonmalignant disease: a randomized phase 2 trial. Bone Marrow Transplant. 2024;59(1):107\u201316.","journal-title":"Bone Marrow Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04213-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04213-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:56:29Z","timestamp":1788184589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04213-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4213"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04213-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest to report.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were conducted in accordance with the ethical standards of the responsible institutional review board and with the tenets of the Helsinki Declaration of 1975, as revised in 2000.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}